ImmuCell Corporation (NASDAQ: ICCC) has received FDA approvalfor its investigational new drug application for a newly formulatedpassive antibody to treat cryptosporidiosis, a diarrhea-like conditionthat can be fatal in individuals with weakened immune systems suchas persons with HIV. A Phase I clinical study will begin by mid-1994.The new formulation is derived from CryptoGam, a product now inPhase I/II clinical trials. ImmuCell's clinical trials are being funded andmanaged by Univax Biologics Inc. of Rockville, Md., under anagreement between the two companies. ImmuCell is based in Portland,Me.ImmuCell's proprietary therapy incorporates antibodies derived fromcolostrum in the milk of cows that have been immunized.Other drugs now undergoing Phase I trials as anti-cryptosporidiumagents are GalaGen's Sporidin-G, which is also derived fromcolostrum, and Biomune's Immuno-C, which is derived from the wheyof cow's milk. - Philippa Maister

(c) 1997 American Health Consultants. All rights reserved.